Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. - Wikidata - awgldk - TriplyDB

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

http://www.wikidata.org/entity/Q38815964

about

The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.Application of Liquid Biopsies in Cancer Targeted Therapy.Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.Platinum sensitivity in metastatic prostate cancer: does histology matter?A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers.PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.PARP inhibitors for homologous recombination-deficient prostate cancer.Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.Advances in liquid biopsy approaches for early detection and monitoring of cancer.The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors.Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.Precision medicine applications in prostate cancer.Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report Molecular Diagnostics in Clinical Oncology Mouse models in the era of large human tumour sequencing studies Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)

P2860

Q40063188-CC1DA614-58FE-4946-9C45-E50EAA4FBD75 Q42634073-F2E676DF-5F8E-4A8A-A652-CDBB423497A2 Q43578455-A2E638A8-6416-4B33-9558-0A974B5ED619 Q46007270-D2D7A4E6-B0FB-4228-B181-94E036F49C60 Q47160372-C6D10FF5-5E95-40DC-A3D3-DC3B08D2F7B5 Q47195375-A9A872B3-97C2-4254-9C56-CD1F8A5614E5 Q47953839-ED7B59B2-0081-446C-980F-12FB5A18AA2D Q48285361-1F68FC84-1478-4A5A-9530-B3510721A397 Q49723005-4EBED035-693E-44F0-8DF8-69DF4503BBD2 Q49728493-C939ECFA-D964-48BF-BA2A-6D76F53A3DFD Q49734875-8FD3DA2B-3CF1-44DE-A1D9-8AF304073937 Q50043843-DF2C4329-701E-4B52-B6DD-E3D0EEE9037B Q50420907-D9EFF32D-1696-4098-B69E-AED7C8B053E1 Q52623144-0D688520-4AE9-4EF3-8A82-515EC7B39273 Q52637922-6090BC68-9D42-43DC-B7FD-2BA0D48686DA Q52646444-D9BB9E6F-C6A2-46CD-97C7-EF02F8D9A1E7 Q54935812-84B62D7B-B8BC-438A-81A9-3C605B09E1BD Q55172706-71C12AC8-3B77-473E-BD3C-63C9ED9F7FD9 Q55230708-308C8460-2329-4E83-83CE-9AC0A8C0BF2C Q55439000-5E704C27-9FF3-4E73-A30D-5C6091862FEA Q57492447-31E5539D-A136-4156-9563-4AE393207D6A Q57826033-26AA1A3B-D84A-4586-AD2E-6EC342278EEA Q58605214-13549D34-15BA-4FE9-8F32-E151CAE6804D Q58700723-0CE566FB-B2A4-4E03-8F59-5E010D68FC3B Q58776633-7B52C351-26D3-40C4-87E9-B0D510BBBD24 Q58799160-CAFCB38E-AEEA-415E-8B50-DB6912325ABF

P2860

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

http://www.wikidata.org/entity/Q38815964

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

@en

type

label

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

@en

prefLabel

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

@en

P1433

Q38815964-055EE590-8677-40A7-8BE8-41E7472E7A2E

P1476

Q38815964-A573BAC0-DDC9-447E-BF13-B99E6C11D8D2

P2093

Q38815964-0171E02A-F48A-4853-96AA-A030B1EF8EB6

Q38815964-1B2036C9-CE36-423C-86E5-5CB6FC633365

Q38815964-1D63A55F-94D2-40DD-86B3-F395371C4F8C

Q38815964-1F66C344-CEB1-4638-97D1-6597C0EBE65E

Q38815964-2DEE72AF-B605-47D3-A2C1-229A7FF9FD29

Q38815964-31C1529F-C26C-490E-BB9F-86B38B02EE5A

Q38815964-32AE7031-3D0A-42F7-A165-C47D2C6E3F29

Q38815964-32ECE12A-83A0-40BE-A869-6DB2FB3BEC42

Q38815964-3B0DDC8F-367D-4A1B-82EC-C68F694C9F4E

Q38815964-3DCDC4BB-2DB1-447B-A7F2-689122331023

P2860

Q38815964-0291DDEE-C6B1-44A3-8192-D3AB2C983148

Q38815964-10FDB951-7A45-4A1E-865E-C9DED876065E

Q38815964-1928E25D-8E72-48BB-8D10-9E8C93C3BA04

Q38815964-2568A2E0-07E9-4AB6-A152-82F7045EF554

Q38815964-25CAA365-1236-4544-A62C-4516FCF4DD64

Q38815964-2704506B-AFAB-4D4B-971E-6A0244CFBAB5

Q38815964-274439F1-507D-4432-AA6D-6D700E762F45

Q38815964-29667A00-7B07-4A82-A80B-97351FC5F749

Q38815964-2F91A736-8343-4410-B65D-4F9CB6217E28

Q38815964-41E771AC-F414-48F2-9C08-B8651466107C

P304

Q38815964-FE904627-8537-4083-ACB1-2C49EB5DE529

P31

Q38815964-FDD3E2A7-F07B-4FE6-B1D4-3A7253E9E07F

P356

Q38815964-9BB523BE-52B9-4570-ABDE-8D9B7552D5D9

P433

Q38815964-6639675C-A79D-4A1E-9B34-9C161F09A6E6

P478

Q38815964-142CFD79-A517-41B3-B921-C0A7F8954736

P50

Q38815964-0F80AC4A-5BB1-4159-96FE-A517230D4AE6

Q38815964-4C844C13-180A-4280-A249-E48F4E219F30

Q38815964-527B46F3-5A2B-49DA-ACBE-AD06496B3FE8

Q38815964-5E0A7F06-2809-436A-8F55-3BA187A2ACF4

Q38815964-6553685A-4A0A-4DF4-A556-568BD5B78F79

Q38815964-A9F0565E-A9FB-43BE-BC2C-B1CE7FD34582

Q38815964-C5F32108-ABE1-4D33-9660-E9CE07BE8D5C

Q38815964-E039F428-DD84-4C04-9C4B-A9FDC0DF6DFB

Q38815964-FB40F10E-2DFE-46ED-888B-4512B3D6E4DF

Q38815964-FE90F511-F3E6-455C-A23A-4005CCFE9234

P577

Q38815964-2C814C7C-AC9D-42C9-AFD3-3427823859C6

P698

Q38815964-D3A79FCA-DFEA-4E74-834C-E468A722F44C

P932

Q38815964-B9045426-7CB6-459B-892D-9E24262A6E9E

P356

2159-8290.CD-17-0261

P1433

Cancer Discovery

P1476

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

@en

P2093

Alexa Gillman

http://www.w3.org/2001/XMLSchema#string

Arul M Chinnaiyan

http://www.w3.org/2001/XMLSchema#string

Berni Ebbs

http://www.w3.org/2001/XMLSchema#string

Claudia Bertan

http://www.w3.org/2001/XMLSchema#string

Dan R Robinson

http://www.w3.org/2001/XMLSchema#string

Daniel Nava Rodrigues

http://www.w3.org/2001/XMLSchema#string

David Dolling

http://www.w3.org/2001/XMLSchema#string

Diletta Bianchini

http://www.w3.org/2001/XMLSchema#string

Gemma Fowler

http://www.w3.org/2001/XMLSchema#string

George Seed

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Resistance to therapy caused by intragenic deletion in BRCA2

The mutational landscape of lethal castration-resistant prostate cancer

Detection of mutations in EGFR in circulating lung-cancer cells

BRCA2 is required for homology-directed repair of chromosomal breaks

P304

1006-1017

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-17-0261

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Christopher J Lord

Pasquale Rescigno

Suzanne Carreira

Shahneen K Sandhu

Johann S de Bono

P577

2017-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28450425

http://www.w3.org/2001/XMLSchema#string

P932

6143169

http://www.w3.org/2001/XMLSchema#string